KEROS THERAPEUTICS INC (KROS) Stock Income Statement
NASDAQ:KROS - Nasdaq - US4923271013 - Common Stock - Currency: USD
| TTM (2025-3-31) | 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 214.71M | 3.55M | 151.00K | 0.00 | 20.10M | |||
| Operating Expenses | 225.02M | 214.38M | 170.09M | 114.79M | 76.47M | |||
| Research and Development | 184.08M | 173.63M | 135.26M | 87.27M | 55.14M | |||
| Selling, General, and Administrative Expenses | 40.94M | 40.75M | 34.83M | 27.53M | 21.33M | |||
| Operating Income | -10.31M | -210.83M | -169.94M | -114.79M | -56.37M | |||
| Interest Income/Expense | 24.48M | 23.50M | 14.76M | 0.00 | 0.00 | |||
| Other Income/Expense | 383.00K | 284.00K | 2.19M | 10.11M | -360.00K | |||
| Income Before Taxes | 14.55M | -187.05M | -152.99M | -104.68M | -56.73M | |||
| Income Tax | N/A | 300.00K | 0.00 | 0.00 | 2.01M | |||
| Net Income | 4.21M | -187.35M | -152.99M | -104.68M | -58.74M | |||
| EBITDA | -9.01M | -209.60M | -169.13M | -114.12M | -55.99M | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -0.18 | -5.00 | -5.20 | -4.15 | -2.52 | |||
| Non GAAP EPS | -0.18 | -5.01 | -5.20 | -4.15 | -2.52 | |||
| Statistics | ||||||||
| Profit Margin | 1.96% | -5277.55% | -101319.21% | N/A | -292.24% | |||
| Operating Profit Margin | -4.80% | -5938.96% | -112543.71% | N/A | -280.45% | |||
All data in USD